BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Big pharma eyes China ‘at forefront of GLP-1 revolution’
Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and Co.’s...

More in BioWorld

BioWorld MedTech

Spectrawave’s Hypervue sees $50M in support
Spectrawave Inc. surfed to a $50 million haul in its series B fundraising round for its Hypervue intravascular imaging system. The company appears to have captured the...

More in BioWorld MedTech

BioWorld Science

Focusing on tumor cells brings insights into cancer neuroscience
By looking at the electrical activity of tumor cells, rather than the neurons that innervate them, investigators at Baylor College of Medicine have added both basic and...

More in BioWorld Science

BioWorld Asia

Detailed data affirm ivonescimab tops Keytruda in NSCLC trial
More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc.,...

More in BioWorld Asia

BioWorld Insider Podcast

The first half of 2024 was strong as M&As and financings dominate. Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024.